Physician profile
Scott Allan Fleischer
NPI 1316050693
$2,839.03
in general payments reported to CMS, 2019-2025
20 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Geriatric Psychiatry provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $34.08 · 2021: $122 · 2022: $201 · 2023: $1,918 · 2024: $64.71 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,210 · Food and Beverage: $1,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,210.13 |
| Food and Beverage | $1,021.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,955.37 | 2019-2025 | Neurostar Tms Therapy System |
| E.R. Squibb & Sons, L.L.C. | $142.73 | 2024-2025 | Cobenfy |
| Allergan, INC. | $92.34 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $80.76 | 2021-2022 | |
| Lundbeck LLC | $71.17 | 2019-2023 | Rexulti |
| Abbvie INC. | $53.22 | 2021-2022 | |
| Axsome Therapeutics, INC. | $50.01 | 2022-2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $47.69 | 2019-2025 | Spravato |
| Shire North American Group INC | $44.23 | 2019 | |
| Sunovion Pharmaceuticals INC. | $42.51 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $42.31 | 2019-2021 | |
| Biogen, INC. | $37.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.15 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.84 | 2024 | Caplyta |
| Livanova USA, INC. | $21.86 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $21.54 | 2025 | Nuplazid |
| Lilly USA, LLC | $19.98 | 2025 | Kisunla |
| Neurocrine Biosciences, INC. | $19.86 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.60 | 2022 | |
| Bausch Health US, LLC | $18.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Fleischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.